Table 1.
Baseline characteristics | Total (n = 30) |
|
---|---|---|
Gender | ||
Female | n (%) | 28 (93.33) |
Male | n (%) | 2 (6.67) |
Age at baseline (years) | Mean ± SD | 56.73 ± 11.48 |
Time since diagnosis, (years) | Mean ± SD | 10.77 ± 5.26 |
Laboratory parameters | ||
ALP (U/L) | Mean ± SD | 126.10 ± 91.13 |
GGT (U/L) | Mean ± SD | 105.73 ± 118.22 |
ALT (U/L) | Mean ± SD | 35.78 ± 26.54 |
AST (U/L) | Mean ± SD | 33.92 ± 18.10 |
TBIL (mg/dL) | Mean ± SD | 0.59 ± 0.31 |
Stage of PBC (at time of diagnosis, according to histology) | ||
Stage I | n (%) | 4 (13.33) |
Stage II | n (%) | 4 (13.33) |
Stage III or IV | n (%) | 5 (16.67) |
Unknown stage | n (%) | 11 (36.67) |
No histology | n (%) | 6 (20) |
Symptoms of PBC | ||
Pruritus | n (%) | 18 (60) |
Asymptomatic | n (%) | 7 (23.33) |
Pruritus and fatigue | n (%) | 5 (16.67) |
Drug dose per body weight (mg/kg/d) | Mean ± SD | 13.89 ± 1.76 |
SD standard deviation, PBC primary biliary cholangitis, ALP alkaline phosphatase, ALT alanine aminotransferase, AST aspartate aminotransferase, GGT gamma glutamyl transpeptidase, TBIL total bilirubin